IQVIA (IQV) MedTech president reports 4,083-share performance award and 1,920-share disposition

Rhea-AI Filing Summary

IQVIA Holdings officer Bhavik Patel reported equity award activity in company stock. On February 8, 2026, he acquired 4,083 shares of common stock at a price of $0, following satisfaction of performance conditions tied to performance-based restricted stock units granted on February 13, 2023.

On the same date, a separate transaction reduced his direct holdings by 1,920 shares at $187.49 per share, leaving him with 3,203 shares of IQVIA common stock held directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Patel Bhavik

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,083	$0.00	--
Tax Withholding	Common Stock	1,920	$187.49	$360K

Holdings After Transaction: Common Stock — 5,123 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Bhavik

(Last) (First) (Middle)

C/O IQVIA HOLDINGS INC.

2400 ELLIS ROAD

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IQVIA HOLDINGS INC. [ IQV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/08/2026		A		4,083(1)	A	$0	5,123	D
Common Stock	02/08/2026		F		1,920	D	$187.49	3,203	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Acquired upon achievement of certain performance criteria pursuant to the performance-based restricted stock units granted on February 13, 2023. The performance conditions applicable to the award were determined to have been satisfied by the Company's Leadership Development and Compensation Committee on February 8, 2026.

Remarks:

President, MedTech and Consumer Health

	/s/ Matthew Gilmartin, Attorney-in-Fact for Bhavik Patel	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Bhavik Patel report at IQVIA (IQV)?

Bhavik Patel reported acquiring 4,083 IQVIA common shares at $0 on February 8, 2026, upon meeting performance criteria for earlier performance-based restricted stock units. A second transaction that day reduced his direct holdings by 1,920 shares at $187.49, leaving him with 3,203 shares.

How many IQVIA (IQV) shares does Bhavik Patel hold after this Form 4?

After the reported transactions, Bhavik Patel directly holds 3,203 shares of IQVIA common stock. This figure reflects the net result of acquiring 4,083 shares for $0 and a separate 1,920-share disposition on February 8, 2026, as disclosed in the Form 4 filing.

What triggered Bhavik Patel’s IQVIA performance-based share acquisition?

The acquisition of 4,083 IQVIA shares was triggered when performance conditions for performance-based restricted stock units, granted on February 13, 2023, were determined satisfied. IQVIA’s Leadership Development and Compensation Committee made this determination on February 8, 2026, leading to the share issuance at no cost.

What were the prices involved in Bhavik Patel’s IQVIA (IQV) transactions?

Patel acquired 4,083 IQVIA shares at a price of $0 per share upon vesting of performance-based units. A separate transaction on the same day involved 1,920 shares at $187.49 per share, which reduced his directly held position to 3,203 shares, according to the Form 4.

What is Bhavik Patel’s role at IQVIA mentioned in the Form 4?

The Form 4 identifies Bhavik Patel as an officer of IQVIA Holdings, with the remarks specifying his title as President, MedTech and Consumer Health. This role information helps investors understand the seniority of the insider involved in the reported equity award transactions.

Are Bhavik Patel’s IQVIA (IQV) transactions direct or through another entity?

Both transactions reported in the Form 4 are categorized as directly owned. The filing lists his ownership form as “D” (direct) for the IQVIA common stock, and the footnote does not state that the shares are held through a separate trust, partnership, or other entity.